Prognostic role of CA15.3 in 7942 patients with operable breast cancer

Breast Cancer Research and Treatment

Volumn 132, Issue 1, 2012, Pages 317-326

  Sandri, M T ^a   Salvatici, M ^a   Botteri, E ^a,b   Passerini, R ^a   Zorzino, L ^a   Rotmensz, N ^a   Luini, A ^a   Mauro, C ^a   Bagnardi, V ^a,c   Cassatella, M C ^a   Bottari, F ^a   Casadio, C ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Biomarker; CA15.3; Early breast cancer; Prognostic value; Tumor marker; Tumor subtypes

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE; KI 67 ANTIGEN; TRASTUZUMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENT CANCER;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; MUCIN-1; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, STEROID; TUMOR MARKERS, BIOLOGICAL;

EID: 84857923466     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1863-x     Document Type: Article

References (37)

1. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151-1159
2. Hilkens J, Buijs F, Hilgers J et al (1984) Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 34:197-206 (Pubitemid 14053141)
3. Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane associated mucin episialian/MUC1. Mol Biol Cell 7:565-577 (Pubitemid 26112564)
4. Fung PYS, Longenecker BM (1991) Specific immunosuppressive activity of epiglycanin, a mucin like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res 51:1170-1176
5. Gimmi CD, Morrison BW, Mainprice BA et al (1996) Breast cancer associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1369-1370
6. Agrawal B, Gendler SJ, Longenecker BM (1998) The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 4:397-403 (Pubitemid 28411034)
7. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, Abba MC (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201:102-110
8. Duffy MJ (1999) CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 36:579-586
9. Duffy MJ, Shering S, Sherry F et al (2000) CA 15-3: a prognostic marker in breast cancer. Int J Biol Markers 15:330-333 (Pubitemid 32041147)
10. Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312 (Pubitemid 350232263)
11. McLaughlin R, McGrath J, Grimes, Given HF (2000) The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 15:340-342 (Pubitemid 32041149)
12. Canizares F, Sola J, Perez M et al (2001) Preoperative values of CA15.3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 22:273-281 (Pubitemid 32823944)
13. Gion M, Boracchi P, Dittardi R et al (2002) Prognostic role of serum CA 15-3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1181-1188 (Pubitemid 34603477)
14. Ebeling FG, Stieber P, Untch M et al (2002) Serum CEA and CA 15-3 as a prognostic factors in primary breast cancer. Br J Cancer 86:1217-1222
15. Kumpulainen EJ, Keskikuru RJ, Johansson RT (2002) Serum tumor marker CA 15-3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat 76:95-102 (Pubitemid 35252485)
16. Molina R, Filella X, Alicarte J et al (2003) Prospective evaluation of CEA and CA15.3 in patients with locoregionale breast cancer. Anticancer Res 23:1035-1042
17. Duffy MJ, Duggan C, Keane R et al (2004) High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 50:559-563 (Pubitemid 38297306)
18. Martin A, Corte MD, Alvarez AM et al (2006) Prognostic value of pre-operative serum CA15.3 levels in breast cancer. Anticancer Res 26:3965-3972
19. Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008) Does the pre-operative value of serum CA15.3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9:445-448
20. Park BW, Oh JW, Kim JH et al (2008) Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann of Oncol 19:675-681 (Pubitemid 351461037)
21. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747
22. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
23. Viale G, Regan MM, Maiorano E et al (2007) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. J Clin Oncol 25:3846-3852
24. Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: Results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569-5575
25. Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23-28
26. Gray RJ (1998) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141-1154
27. Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551-561 (Pubitemid 19116001)
28. Antolini L, Nam B-H, D'Agostino RB (2004) Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Comm Statist Theory Methods 33:2117-2135
29. Davis BW, Gelber RD, Goldhirsch A et al (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58:2662-2670 (Pubitemid 17232925)
30. Layfield LJ, Goldstein N, Perkinson KR, Proia AD (2003) Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 9:257-259 (Pubitemid 36627180)
31. Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12:10-19 (Pubitemid 40614485)
32. Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038 (Pubitemid 46638937)
33. Mukhopadhyay P, Chakraborty S, Ponnusamy MP et al (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815: 224-240
34. Perou C, Sorlie T, Elsen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
35. Sorlie T, Perou AM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
36. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
37. Viale G, Rotmensz N, Maisonneuve P et al (2009) Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 116:317-328